We are live on !
Find out more
Fairmount Funds Management Portfolio holdings
AUM
$1.51B
Turnover
15.38%
1-Year Est. Return
546.08%
This Fund
S&P 500
This Quarter Est. Return
+32.66%
1 Year Est. Return
+546.08%
3 Year Est. Return
+2,136.34%
5 Year Est. Return
+8,050.66%
10 Year Est. Return
–
AUM
$1.51B
AUM Growth
+$129M
(+9.3%)
Cap. Flow
-$167M
Cap. Flow % of AUM
Cap. Flow %
-11.04%
Top 10 Holdings %
Top 10 Hldgs %
97.65%
Holding
13
New
1
Increased
1
Reduced
–
Closed
1
Avg Time Held
2.3
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$19M |
| 2 |
Faeth Therapeutics
FTH
|
+$16.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Spyre Therapeutics
SYRE
|
+$203M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Oruka Therapeutics
ORKA
$4.98B
| $353M | 23.31% |
3,705,262
| – | – |
2024 Q3
7 quarters
|
|
2
Dianthus Therapeutics
DNTH
$4.24B
| $247M | 16.35% |
2,537,191
| – | – |
2023 Q3
11 quarters
|
|
|
DMRA
3
Damora Therapeutics
DMRA
$1.2B
| $227M | 14.98% |
8,713,000
| – | – |
2026 Q1
1 quarter
|
|
4
Cogent Biosciences
COGT
$5.18B
| $213M | 14.08% |
5,503,418
| – | – |
2020 Q3
23 quarters
|
|
5
Jade Biosciences
JBIO
$876M
| $101M | 6.69% |
4,553,494
| – | – |
2025 Q2
4 quarters
|
|
6
Enliven Therapeutics
ELVN
$2.81B
| $94.2M | 6.22% |
1,855,644
| – | – |
2022 Q4
14 quarters
|
|
|
7
Viridian Therapeutics
VRDN
$2.32B
| $93.5M | 6.18% |
5,090,928
+1,176,470
| +30% | +$19M |
2020 Q4
22 quarters
|
|
8
Zenas BioPharma
ZBIO
$1.78B
| $59.9M | 3.96% |
2,359,025
| – | – |
2024 Q3
7 quarters
|
|
9
Crescent Biopharma
CBIO
$463M
| $49.5M | 3.27% |
2,747,866
| – | – |
2025 Q2
4 quarters
|
|
10
DELISTED
Apogee Therapeutics
APGE
| $39.6M | 2.62% |
298,647
| – | – |
2023 Q3
11 quarters
|
|
|
11
Faeth Therapeutics
FTH
$496M
| $18.1M | 1.19% |
+722,020
| New | +$16.7M |
2026 Q2
0 quarters
|
|
12
Inhibikase Therapeutics
IKT
$227M
| $17.5M | 1.16% |
8,625,000
| – | – |
2024 Q4
6 quarters
|
|
|
13
Spyre Therapeutics
SYRE
$8.01B
| – | – |
-4,018,101
| Closed | -$203M | – |
|
Similar funds
Fairmount Funds Management's Q2 2026 Portfolio in Review
As of Q2 2026, Fairmount Funds Management held 13 positions worth $1.51B, up 9.3% from $1.38B the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Fairmount Funds Management withdrew a net $167M in Q2 2026, closing 1 position. Its most notable exit was Spyre Therapeutics, an estimated $203M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Fairmount Funds Management opened a new position in Faeth Therapeutics worth $18.1M.
- Fairmount Funds Management's largest Q2 2026 buy was Faeth Therapeutics: 722,020 shares worth $18.1M.
- Fairmount Funds Management added most to Viridian Therapeutics in Q2 2026, an estimated $19M increase.
- Fairmount Funds Management fully exited Spyre Therapeutics in Q2 2026, selling an estimated $203M.
- Fairmount Funds Management's ten largest holdings make up 98% of its $1.51B portfolio in Q2 2026.
- Fairmount Funds Management opened 1 new position and closed 1 in Q2 2026.
- Fairmount Funds Management's portfolio value rose 9.3% quarter-over-quarter to $1.51B.
Based on Fairmount Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.